A Secondary Finding in a Research Exome Returned to a Family
A 9-year-old boy is enrolled in a research exome study for undiagnosed developmental delay and hypotonia. The research protocol returns only variants in a defined list of actionable secondary-finding genes. The analysis identifies a pathogenic BRCA2 frameshift in the child, inherited from his father, who is 41 and has not been tested. The family is also told that no primary diagnosis was found. The mother asks whether the BRCA2 result means her son will get cancer, whether she should be tested, and whether the result can be used to get insurance for the family. The research consent form stated that secondary findings would be returned but did not specify a process for adult-onset conditions in minors.
1. How should the team handle the return of an adult-onset, medically actionable finding in a 9-year-old?
Read the worked answer
BRCA2 is on the ACMG secondary-findings list, and pathogenic BRCA2 is actionable in adulthood (surveillance, risk-reducing surgery). For a child, the standard is that predictive testing for adult-onset conditions is generally deferred until the individual can consent - but this is a secondary finding from a test already done for another indication, not a targeted predictive test. The team should:
- Return the result to the parents as information relevant to the family, framing it as primarily actionable for the father and other adults.
- Be explicit that the child's own risk is real but that interventions begin in adulthood; no childhood surveillance is indicated for BRCA2 based on current guidelines.
- Recommend the father pursue confirmatory testing and cascade testing; the father's result is the immediately actionable one.
- Flag the consent gap: the protocol did not specify a process for adult-onset findings in minors. This should be reviewed by the IRB and the consent/assent process amended.
The judgment: distinguishing a secondary finding from a predictive test, and not letting the child's result substitute for the father's needed evaluation.
2. The mother asks whether her son 'will get cancer.' How should this be answered?
Read the worked answer
Answer with accurate, non-deterministic framing:
- A pathogenic BRCA2 variant confers substantially increased lifetime risk of breast, ovarian, pancreatic, prostate, and melanoma cancers - but it is a risk, not a certainty; many carriers never develop cancer, and risk is modified by other factors.
- For a male, the most relevant risks are breast (elevated but still uncommon), prostate, and pancreatic cancer; risk management guidelines for men exist and begin in adulthood.
- Emphasize that nothing needs to be done now for the child, and that the information is most useful to the father and to the child when he is an adult.
- Avoid giving numeric lifetime risks that are not validated for this specific variant and family; offer genetics follow-up for the father.
Also address the emotional layer: the parents may feel the result is a burden. Acknowledge that and offer counseling.
3. How should the team respond to the insurance question?
Read the worked answer
Be factual and avoid legal advice beyond scope:
- In the U.S., GINA protects against health insurance and employment discrimination based on genetic information, but does NOT cover life, disability, or long-term-care insurance.
- The family should be told this distinction clearly, because the question often hides a life-insurance concern.
- Recommend they consult with the study's genetic counselor or a patient advocacy organization before making insurance decisions; some families choose to obtain life/disability coverage before results are documented.
- Document that this discussion occurred.
The judgment: knowing the boundaries of GINA and not overpromising protection.